Clinical Trial Update: Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating CHF 6001 delivered via Nexthaler inhaler versus capsule for oral inhalation via Aerolizer in chronic obstructive pulmon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF 6001

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: COPD | Phase 1 | Status: COMPLETED